SCHEMBL256102

SCHEMBL256102

Brc1cnc(OC2CCC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HMOX1 P09601 1/20 0.42
ACACB O00763 18/20 0.38
LRRK2 Q5S007 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164350 0.96 HMOX1 (0.42) HMOX1ACACBLRRK2
SCHEMBL16691214 0.94 HMOX1 (0.41) HMOX1ACACBLRRK2
SCHEMBL18444799 0.91 HMOX1 (0.43) HMOX1ACACB
SCHEMBL14968025 0.88 HMOX1 (0.40) HMOX1ACACB
SCHEMBL631937 0.82 HMOX1 (0.42) HMOX1ACACBLRRK2
SCHEMBL12525729 0.82 HMOX1 (0.39) HMOX1ACACBLRRK2
Hydrochloric Acid SCHEMBL4711714 0.81 HRH1 (0.42) HMOX1
SCHEMBL2536718 0.79 HRH3 (0.44) HMOX1
SCHEMBL22396859 0.79 ACACB (0.41) ACACB
SCHEMBL17972939 0.79 ACACB (0.41) ACACBLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114984003-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-08-27 CN disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
US-11524938-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-13 US disclosed
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US disclosed
CN-115054600-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-16 CN disclosed
CN-114984003-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-02 CN disclosed
US-11390623-B2 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands PFIZER INC. (US) 2022-07-19 US disclosed
CN-109415321-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-06-17 CN disclosed
CN-108884093-B Dopamine D3 ligand compound 辉瑞公司 2021-07-09 CN disclosed
EP-3763704-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2021-01-13 EP disclosed
US-20130172316-A1 New azetidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 US disclosed
US-20130172316-A1 New azetidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 US disclosed
WO-2013092616-A1 NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-27 WO disclosed
WO-2013092616-A1 NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-27 WO disclosed
US-20130158004-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158004-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158004-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
WO-2012028676-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 HMOX1 3228/4885ACACB 642/4885LRRK2 3597/4885
US-11524938-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 HMOX1 3228/4885ACACB 642/4885LRRK2 3597/4885
US-20130172316-A1 New azetidine derivatives, pharmaceutical compositions and uses thereof QDPR, AZI2, CYP2C19 HMOX1 1679/4885ACACB 4697/4885LRRK2 4230/4885
US-20130158004-A1 Azetidine Derivatives GPR119, LIPE, LPL HMOX1 1672/4885ACACB 870/4885LRRK2 3187/4885
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof ABCG2, PGA5, PDE6G HMOX1 2457/4885ACACB 2257/4885LRRK2 4151/4885
US-11390623-B2 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands DRD3, DRD2, DRD4 HMOX1 4115/4885ACACB 3991/4885LRRK2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.